Psychotic symptoms, among others, are present in Schizophrenia. The most severe developments during the moments of exacerbation, are meliorated after this period, although they do not absolutely disappear in the majority of the cases. Anti psychotic drugs are key in the treatment. As far as it is known, the efficacy of these drugs is due to the dopaminergic blockade. Nevertheless, the rythm, and the universal validity of this treatment actually have an heterogeneous character. At this moment, various medication algorithms are available, which are usefull in the orientation of the medical prescription. The comparative analysis and the practical conclusions are necessary for a correct management of them.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Psychotic symptoms may manifest in Alzheimer's disease (AD), especially in advanced disease stages and in patients with higher polygenic risk scores for schizophrenia (SCZ-PRS). Such genetic risk seems also to influence grey matter volume (GMV) alterations in patients with psychosis. Since multiple neurotransmitter systems, namely dopamine (DA) and serotonin (5-HT), have been implicated in psychosis, the aim of this study was to investigate whether a SCZ-PRS may explain variance in the association between GMV and the cerebral distribution of DA and 5-HT.
View Article and Find Full Text PDFBackground: Neuropsychiatric symptoms (NPS) constitute a major challenge for patients with Alzheimer's disease (AD). We have recently demonstrated that in AD, overall NPS burden is significantly associated with patient function. However, few studies have examined the relationship between specific symptom clusters with neurological biomarkers.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Background: Individuals diagnosed with COVID-19 may continue to experience symptoms long after infection. Research suggests that the COVID-19 virus may be linked to brain pathology and dementia risk, possibly due to neurological complications and long-term cognitive effects. Mild Behavioral Impairment (MBI) is an early indicator of dementia risk characterized by later life onset of persistent changes in behavior or personality.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
King's College London, London, United Kingdom; College of Medicine and Health, University of Exeter, Exeter, United Kingdom.
Psychosis is a common and distressing disorder in people with Alzheimer disease, associated with a poor clinical prognosis, an increased risk of institutionalization and for which there are no approved treatments. New approaches to diagnosis and symptom assessment and treatment are beginning to move the field forward, including the emergence of psychosis at the pre-clinical or even pre-cognitive impairment stages of disease in some individuals. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) research criteria for psychosis in neurodegenerative disease, and the ISTAART criteria for mild behavioural impairment are examples of recent developments.
View Article and Find Full Text PDFBackground: We present Phase 1 trial data using the Neuropsychiatric Inventory ("NPI") domains, NPI-delusions and NPI-hallucinations as symptoms of psychosis in participants with Alzheimer's ("AD") receiving IGC-AD1, a combination of low concentration delta 9-tetrahydrocannabinol ("THC") and melatonin. Cannabis use is considered an established risk factor for psychosis in young people. Psychosis is prevalent in AD patients, with around 50% experiencing it, generating safety concerns regarding the use of THC in these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!